Along with clinical improvements, a reduction in some of the lung cancer‐related symptoms and improved HRQoL have also been reported in patients who received a PD‐(L)1 inhibitor as a second‐line therapy compared to those who were treated with docetaxel.12, 18, 19. This evidence concerns the gene CD274 and lung carcinoma.